MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1878313

Maia Biotechnology, INC. 8-K Filing Summary
FieldDetail
CompanyMaia Biotechnology, INC. (MAIA)
Form Type8-K
Filed DateDec 20, 2024
Risk Levellow
Pages3
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC filing, corporate reporting

TL;DR

MAIA Bio filed an 8-K on Dec 20 for events on Dec 16. Standard reporting.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on December 20, 2024, reporting events as of December 16, 2024. The filing pertains to "Other Events" and "Financial Statements and Exhibits." The company is incorporated in Delaware and its principal executive offices are located in Chicago, IL.

Why It Matters

This 8-K filing indicates routine corporate reporting, providing updates on significant events and financial disclosures for MAIA Biotechnology, Inc.

Risk Assessment

Risk Level: low — This filing appears to be a routine 8-K for other events and exhibits, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for MAIA Biotechnology, Inc.?

The primary purpose of this 8-K filing is to report on "Other Events" and "Financial Statements and Exhibits" as of December 16, 2024.

When was this 8-K report filed with the SEC?

This 8-K report was filed on December 20, 2024.

Where are MAIA Biotechnology, Inc.'s principal executive offices located?

MAIA Biotechnology, Inc.'s principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

What is the state of incorporation for MAIA Biotechnology, Inc.?

MAIA Biotechnology, Inc. is incorporated in Delaware.

What is the SEC file number for MAIA Biotechnology, Inc.?

The SEC file number for MAIA Biotechnology, Inc. is 001-41455.

Filing Stats: 781 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2024-12-20 13:05:54

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 20, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing